Compositions, systems, and methods for treating cancer, tumor treatment fields, and VEGF inhibitors
JP2025520608A5Pending Publication Date: 2026-06-26NOVOCURE GMBH CH
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024574777
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-28
- Filing Date
- 2023-06-20
- Publication Date
- 2026-06-26
AI Technical Summary
Technical Problem
Current treatments for glioblastoma multiforme (GBM), such as bevacizumab and tumor treating fields (TTFields), face challenges with patient resistance and limited survival benefits, necessitating a more effective combination therapy.
Method used
Combining an alternating electric field (TTFields) with small molecule anti-angiogenic agents that specifically interact with vascular endothelial growth factor (VEGF) or its receptor (VEGFR) to inhibit their interaction and signaling, thereby reducing cancer cell survival and tumor volume.
Benefits of technology
This combination therapy demonstrates a synergistic effect in reducing cancer cell survival rates and tumor volume, potentially overcoming resistance and improving treatment outcomes.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
Disclosed are compositions, systems, and methods for reducing the survival rate of cancer cells, treating cancer, and preventing an increase in the volume of tumors present in the body of a living being. The systems and methods include applying an alternating magnetic field in combination with the administration of at least one composition comprising at least one small molecule anti-angiogenic agent that specifically interacts with VEGF.
Need to check novelty before this filing date? Find Prior Art